✦ LIBER ✦

Latency and reactivation of a precore mutant hepatitis B virus in a chronically infected patient

✍ Scribed by Raimondo, Giovanni; Stemler, Marietta; Schneider, Ralf; Wildner, Gerhild; Squadrito, Giuseppe; Will, Hans

Book ID: 122030405
Publisher: Elsevier Science
Year: 1990
Tongue: English
Weight: 434 KB
Volume: 11
Category: Article
ISSN: 0168-8278
DOI: 10.1016/0168-8278(90)90224-F

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Reactivation of precore mutant hepatitis

Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients

✍ Ming-Shen Dai; Jang-Jih Lu; Yeu-Chin Chen; Cherng-Lih Perng; Tsu-Yi Chao 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views

## BACKGROUND. A point mutation from G to A at nucleotide (nt) 1896 of the precore region of hepatitis B virus (HBV) DNA has been shown to be associated with fulminant and severe hepatitis. Further studies have suggested that this point mutation, together with additional mutations in the precore p

Selection of a precore mutant of hepatit

Selection of a precore mutant of hepatitis B virus and reactivation of chronic hepatitis B acquired in childhood

✍ F. Bortolotti; C. Crivellaro; M.R. Brunetto; P. Cardrobbi; A. Bertolini; A. Albe 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 226 KB

Hepatitis B Exacerbation with a Precore

Hepatitis B Exacerbation with a Precore Mutant Virus Following Withdrawal of Lamivudine in a Human Immunodeficiency Virus-infected Patient

✍ D. Neau; E. Schvoerer; D. Robert; F. Dubois; H. Dutronc; H.J.A. Fleury; J.M. Rag 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Precore stop mutant in anti-HBe-positive

Precore stop mutant in anti-HBe-positive phases of chronic hepatitis B virus infection

✍ Chia-Ming Chu 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 31 KB

Efficacy of lamivudine in patients with

Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB

✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60

Absence of hepatitis B virus precore mut

Absence of hepatitis B virus precore mutants in patients with chronic hepatitis B responding to interferon-α

✍ Jianye Xu; David Brown; Tim Harrison; Yue Lin; Geoffrey Dusheiko 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 614 KB

Precore defective HBV mutants may gradually prevail because of immune selection and explain spontaneous seroconversion from HBeAg to anti-HBe in HBV carriers. We have analyzed whether the presence of precore HBV mutants is a determinant of responsiveness to interferon-a therapy. Fifteen carriers (ni